Diffusion Therapeutics (DFTX) Drops 9% Ahead of Anxiety Disorder Clinical Data

DFTX Definium Therapeutics Inc

$36.23 -3.13%

View chart & analysis →

1. 1Diffusion Therapeutics (DFTX) shares fell 9% on Tuesday, headed for their worst day since early November.
2. 2Results from the once-daily treatment DT120 in a late-stage clinical trial for generalized anxiety disorder are due this week (week of Aug. 10), with data from a second anxiety study set for September.
3. 3The market is watching to see whether the benefits already demonstrated in depression extend to anxiety disorders.

Source Stocktwits +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →